Immix Biopharma Inc 2026年季度报告

FORM 10-Q (Mark One) For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41159 IMMIX BIOPHARMA, INC.(Exact Name of Registrant as Specified in its Charter) Delaware45-4869378(State or other jurisdictionof incorporation or organization)(I.R.S. EmployerIdentification No.) 11400 West Olympic Blvd., Suite 200, Los Angeles, CA90064(Address of principal executive offices)(Zip Code) (310) 651-8041(Registrant’s telephone number, including area code) Not applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Trading Symbol(s)IMMX Name of each exchange on which registeredThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐ Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Number of shares of common stock outstanding as of April 30, 2026 was 54,411,427. PageNo.PART I. FINANCIAL INFORMATIONItem 1.Financial Statements5Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20255Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31,2026 and 2025 (Unaudited)6Condensed Consolidated Statements of Stockholders’ Equity for the Three Months ended March 31, 2026 and 2025(Unaudited)7Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2026 and 2025(Unaudited)8Notes to the Condensed Consolidated Financial Statements (Unaudited)9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures About Market Risk32Item 4.Controls and Procedures32PART II. OTHER INFORMATIONItem 1.Legal Proceedings33Item 1A.Risk Factors33Item 2.Unregistered Sales of Equity Securities and Use of Proceeds33Item 5.Other Information33Item 6.Exhibits34Signatures352 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions ofSection 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934,as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,”“expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these termsor other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates andprojections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. Wemay not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or eventscould differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and ourforward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertaintiesinherent in our statements regarding: ●our projected financial position and estimated cash burn rate;●our estimates regarding expenses, future revenues and capital requirements;●our ability to maintain the listing of our common stock, par value $0.0001 per share (the “common stock”), on theNasdaq Capital Market (“Nasdaq”);●our need to raise substantial additional ca